Arriving in the landscape of excess body fat treatment, retatrutide presents a different method. Unlike many existing medications, retatrutide works as a double agonist, concurrently targeting both GLP-like peptide-1 (GLP-1) and glucose-sensitive insulinotropic substance (GIP) receptors. This concurrent activation promotes multiple helpful effects,